Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
An established pharmaceutical strategy to increase oral drug absorption of low solubility-high permeability drugs is to create nanoparticles of them. Reducing the size of the solid-state particles increases their dissolution and transport rate across the mucus barrier and the aqueous boundary layer....
Saved in:
Main Authors: | David Dahlgren (Author), Erik Sjögren (Author), Hans Lennernäs (Author) |
---|---|
Format: | Book |
Published: |
International Association of Physical Chemists (IAPC),
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches
by: David Dahlgren, et al.
Published: (2019) -
BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide
by: Milica Markovic, et al.
Published: (2020) -
The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin
by: David Dahlgren, et al.
Published: (2020) -
On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet
by: Varun Kushwah, et al.
Published: (2021) -
Prediction of in vivo intestinal hydrolysis and absorption of prodrug from in vitro data
by: Keiichirou Tanaka, et al.
Published: (2012)